How large is the multiomics services market?

The market size of multiomics services in 2027 is calculated to be USD 1.68 billion.

What are the growth projections for the multiomics services industry?

Multiomics Services Market size stood at USD 1.45 billion in 2026 and is predicted to grow at a 18.1% CAGR from 2027 to 2036, crossing USD 7.65 billion by 2036.

How is multiomics adoption influencing research and clinical workflows?

Multiomics enables integrated analysis across multiple molecular layers, supporting deeper disease understanding, biomarker discovery, patient assessment, and therapeutic research. Its broader use is strengthening demand for specialized services across discovery and clinical applications.

Why is precision medicine creating sustained demand for multiomics services?

Precision medicine requires detailed insight into individual biological characteristics and disease variability. Multiomics supports patient stratification, treatment selection, biomarker discovery, and therapeutic monitoring through integrated molecular profiles, reinforcing its role in personalized care strategies.

Why do pharmaceutical and biotechnology companies dominate the multiomics services market?

Pharmaceutical and biotechnology companies accounted for 48.09% of the market in 2026, driven by demand for integrated molecular insights that support biomarker identification, therapeutic target discovery, disease characterization, and precision medicine research.

How is drug discovery and development driving growth in the multiomics services market?

Drug discovery and development accounted for 38.29% of the market in 2026 and is also the fastest-growing application segment, as researchers use integrated molecular data to identify targets, characterize disease pathways, evaluate drug responses, and advance targeted therapies.

How does North America maintain its leadership in the multiomics services market?

North America accounted for 42.54% market share in 2026, supported by advanced life sciences infrastructure, established genomics and proteomics capabilities, and demand for integrated biological analysis in drug discovery and precision medicine.

Why is Asia Pacific emerging as a major growth market for multiomics services?

Asia Pacific is expected to grow fastest as life sciences research, biotechnology activity, and investments in genomics and precision medicine increase demand for integrated omics analysis, biomarker identification, and personalized healthcare research.

Which companies are driving growth in the multiomics services landscape?

Prominent players in the multiomics services market include Thermo Fisher Scientific (USA), Illumina (USA), BGI Genomics (China), Qiagen (Netherlands), Eurofins Scientific (Luxembourg), GenScript (China), Novogene (China), Roche Diagnostics (Switzerland), Agilent Technologies (USA), Macrogen (South Korea).